K. Allegaert, M. Rayyan, V. Cossey, and C. Van Geet, “Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease”, J Pediatr Neonat Individual Med, vol. 4, no. 1, p. e040104, Jan. 2015.